Cardinal Health, Inc. (BMV:CAH)
Mexico · Delayed Price · Currency is MXN | Market Cap | 904.92B +39.7% |
| Revenue (ttm) | 4.44T +14.2% |
| Net Income | 29.95B +9.8% |
| EPS | 126.33 +12.1% |
| Shares Out | n/a |
| PE Ratio | 30.22 |
| Forward PE | 17.91 |
| Dividend | 36.16 (0.89%) |
| Ex-Dividend Date | Oct 1, 2026 |
| Volume | 22 |
| Open | 4,054.20 |
| Previous Close | 4,052.80 |
| Day's Range | 4,054.20 - 4,054.20 |
| 52-Week Range | 2,706.36 - 4,054.20 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Oct 30, 2026 |
About Cardinal Health
Cardinal Health, Inc. operates as a healthcare services and products company in the United States and internationally. It operates in two segments: Pharmaceutical and Specialty Solutions, and Global Medical Products and Distribution. The company offers customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories, physician offices, and patients in the home. It distributes branded and generic pharmaceutical, specialty pharmaceutical, and over-the-counter healthcare and consumer products. T... [Read more]
Financial Performance
In fiscal year 2026, Cardinal Health's revenue was $254.25 billion, an increase of 14.23% compared to the previous year's $222.58 billion. Earnings were $1.71 billion, an increase of 9.80%.
Financial numbers in USD Financial StatementsNews
Cardinal Health Transcript: 2026 Global Healthcare Conference
All five segments delivered strong double-digit earnings growth, with specialty and pharma outperforming expectations. Strategic acquisitions and operational improvements are driving sustainable growth, while contract structures and a stable customer base support consistency. Cash flow targets are nearly achieved, and at-home solutions are focused on scalable, automated delivery.
Cardinal Health Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
Fiscal 2027 guidance projects 13%-15% EPS growth, driven by strong performance across all segments and continued investment in specialty, pharma, and at-home solutions. Strategic customer relationships, diversified revenue streams, and proactive policy management support long-term growth and resilience.
Cardinal Health Transcript: Wells Fargo 21st Annual Healthcare Conference
Strong FY 2026 results were driven by specialty and generics, with FY 2027 guidance above long-term targets. Growth is supported by acquisitions, robust specialty and nuclear businesses, and disciplined capital allocation, while AI and cost optimization remain key priorities.
Cardinal Health Earnings Call Transcript: Q4 2026
Q4 and fiscal 2026 saw strong revenue, profit, and cash flow growth, led by Pharmaceutical and Specialty Solutions and other growth businesses. Fiscal 2027 guidance calls for double-digit EPS and profit growth, continued investment, and robust capital returns, with risks from tariffs, input costs, and regulatory changes.
Cardinal Health Earnings release: Q4 2026
Cardinal Health released its Q4 2026 earnings on August 11, 2026, summarizing the period's financial results.
Cardinal Health Slides: Q4 2026
Cardinal Health has posted slides in relation to its Q4 2026 quarterly earnings report, which was published on August 11, 2026.
Cardinal Health Annual report: Q4 2026
Cardinal Health has published its Q4 2026 annual report on August 11, 2026.
Cardinal Health forecasts full-year profit above estimates on specialty drug strength
U.S. drug distributor Cardinal Health on Tuesday forecast fiscal 2027 profit well above Wall Street expectations after topping fourth-quarter profit estimates, driven by sustained demand for special...
Can Cardinal Health's Strong Earnings Guidance Offset a Mixed Quarter?
Cardinal Health reports mixed quarterly performance across its business segments as earnings get a lift from one-time tariff refunds.
Cardinal Health Logs Mixed Sales, Sees Growth in New Year
Cardinal Health had a mixed fiscal fourth quarter in terms of sales across its two main business lines, but expects revenue to rise in both segments in the new fiscal year.
Cardinal Health Reports Fourth Quarter and Fiscal Year 2026 Results and Provides Fiscal Year 2027 Guidance
Fourth quarter revenue increased 6% to $63.7 billion Fourth quarter GAAP 1 diluted EPS increased 70% to $1.70 Excluding a one-time positive impact of $0.31 from the recognition of the IEEPA tariff ref...
Cardinal Health Board of Directors Approves Quarterly Dividend
DUBLIN, Ohio,, Aug. 11, 2026 /PRNewswire/ -- Cardinal Health (NYSE: CAH) announced today that its Board of Directors approved its quarterly dividend of $0.5158 per share, out of the Company's capital ...
Cardinal Health to buy AdaptHealth diabetes unit, Strive Medical for $360 million
Cardinal Health said on Monday it has agreed to buy AdaptHealth's diabetes health business and medical supply provider Strive Medical in separate deals for about $360 million in total, expanding its...
Cardinal Health expands home care business with two tuck-in acquisitions
DUBLIN, Ohio, July 20, 2026 /PRNewswire/ -- Cardinal Health (NYSE: CAH) announced today it has entered into two definitive agreements that accelerate its at-Home Solutions' growth strategy. Cardinal H...
Cardinal Health to Announce Fourth-Quarter and Year-End Results for Fiscal Year 2026 on August 11
DUBLIN, Ohio, July 9, 2026 /PRNewswire/ -- Cardinal Health (NYSE: CAH) plans to release fourth-quarter and year-end financial results for its fiscal year 2026 on August 11, prior to the opening of tra...
Neurocrine Biosciences Presents First Retrospective Case Series of CRENESSITY® (crinecerfont) in Patients with Classic Congenital Adrenal Hyperplasia Due to 11β‑Hydroxylase Deficiency at ENDO 2026
Androstenedione and other adrenal hormone levels in 11β‑hydroxylase-deficient patients improved substantially after initiation of CRENESSITY, with >90% median reductions in 11-deoxycortisol and 11-deo...
Cardinal Health Transcript: Bank of America Global Healthcare Conference 2026
Strong Q3 profit growth and raised guidance reflect robust demand and operational execution across all segments. Strategic M&A in GI and urology, investments in innovation, and disciplined capital allocation support long-term growth and resilience.
Cardinal Health Earnings Call Transcript: Q3 2026
Q3 saw double-digit revenue and profit growth, led by specialty and pharma, with robust results in other growth businesses. Guidance for EPS and free cash flow was raised, reflecting operational strength, tax benefits, and successful M&A integration.
Cardinal Health Earnings release: Q3 2026
Cardinal Health released its Q3 2026 earnings on April 30, 2026, summarizing the period's financial results.
Cardinal Health Slides: Q3 2026
Cardinal Health has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on April 30, 2026.
Cardinal Health Quarterly report: Q3 2026
Cardinal Health has published its Q3 2026 quarterly earnings report on April 30, 2026.
Cardinal Health Rises. A Guidance Hike Powers the Stock Past These Weak Points.
Cardinal Health raises its fiscal-year adjusted earnings guidance for the second time this year, helping investors look past mixed quarterly performance.
Cardinal Health Lifts Outlook Again as Revenue Rises
Cardinal Health once again raised its full-year outlook after logging higher-than-expected adjusted earnings in the third quarter.
Cardinal Health lifts annual profit forecast on strong demand for specialty drugs
Drug distributor Cardinal Health on Thursday raised its 2026 profit forecast range, betting on strong demand for costly specialty medicines and branded drugs at its pharmaceuticals unit.